Literature DB >> 30567235

Treatment of advanced stage methotrexate-associated lymphoproliferative disorders (MTX-LPDs) with methotrexate discontinuation.

Yael Ross1, Mohammad Kamran2.   

Abstract

We present two cases of patient's with long-standing autoimmune diseases being treated with immunosuppressants that developed aggressive lymphoproliferative disorders. Immunosuppressants have a well-known association with disorders. Sustained regression of these lymphoproliferative disorders occurred with simple discontinuation of these immunosuppressive agents. © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  malignant disease and immunosuppression; musculoskeletal syndromes; rheumatoid arthritis; rheumatology; therapeutic indications

Mesh：

Substances：

Year:  2018        PMID： 30567235      PMCID： PMC6301593          DOI： 10.1136/bcr-2018-226545

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  11 in total

1.  The aggressive clinical courses of Hodgkin lymphoma primarily diagnosed as methotrexate-induced non-specific lymphoproliferative disorder in patients with rheumatoid arthritis.

Authors:  Michihide Tokuhira; Takayuki Tabayashi; Yuka Tanaka; Yasuyuki Takahashi; Yuta Kimura; Tatsuki Tomikawa; Tomoe Anan-Nemoto; Shuju Momose; Morihiro Higashi; Ayumi Okuyama; Reiko Watanabe; Koichi Amano; Jun-Ichi Tamaru; Masahiro Kizaki
Journal:  J Clin Exp Hematop       Date:  2017

2.  Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France.

Authors:  Xavier Mariette; Dominique Cazals-Hatem; Josiane Warszawki; Frédéric Liote; Nathalie Balandraud; Jean Sibilia
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

3.  Spontaneous Regression of Methotrexate-related Lymphoproliferative Disorder with T-cell Large Granular Lymphocytosis.

Authors:  Hiroshi Ureshino; Chiho Kadota; Kazuya Kurogi; Masaharu Miyahara; Shinya Kimura
Journal:  Intern Med       Date:  2015-09-01       Impact factor: 1.271

4.  Successful treatment of immunodeficiency-associated EBV-negative lymphoproliferative disorders in rheumatoid arthritis by methotrexate withdrawal and prevention of its relapse by rituximab administration.

Authors:  Noriaki Kawano; Nobuyuki Ono; Shuro Yoshida; Takuro Kuriyama; Kiyoshi Yamashita; Kiichiro Beppu; Yoshiya Shimao; Kosuke Marutsuka; Yuji Ueda; Akira Ueda
Journal:  J Clin Exp Hematop       Date:  2012

5.  Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.

Authors:  Ayako Ichikawa; Fumiko Arakawa; Junichi Kiyasu; Kensaku Sato; Hiroaki Miyoshi; Daisuke Niino; Yoshizo Kimura; Masanori Takeuchi; Maki Yoshida; Yukinao Ishibashi; Shinji Nakashima; Yasuo Sugita; Osamu Miura; Koichi Ohshima
Journal:  Eur J Haematol       Date:  2013-05-13       Impact factor: 2.997

6.  Reversible methotrexate-associated lymphoma of the liver in rheumatoid arthritis: a unique case of primary hepatic lymphoma.

Authors:  Ai Kawahara; Junichi Tsukada; Takahiro Yamaguchi; Takefumi Katsuragi; Takehiro Higashi
Journal:  Biomark Res       Date:  2015-05-06

7.  Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: Comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types.

Authors:  Yuka Gion; Noriko Iwaki; Katsuyoshi Takata; Mai Takeuchi; Keiichiro Nishida; Yorihisa Orita; Tomoyasu Tachibana; Tadashi Yoshino; Yasuharu Sato
Journal:  Cancer Sci       Date:  2017-05-23       Impact factor: 6.716

8.  Complete Remission of Methotrexate-Related Epstein-Barr-Virus-Associated Hodgkin-Like Lymphoma following Withdrawal of MTX Coupled with Clarithromycin Administration.

Authors:  Nobuo Takemori; Hiroyuki Kaneko; Masaya Nakamura; Masaru Kojima
Journal:  Case Rep Hematol       Date:  2012-12-19

9.  The usefulness of (18)F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD).

Authors:  Shiro Watanabe; Osamu Manabe; Kenji Hirata; Noriko Oyama-Manabe; Naoya Hattori; Yasuka Kikuchi; Kentaro Kobayashi; Takuya Toyonaga; Nagara Tamaki
Journal:  BMC Cancer       Date:  2016-08-15       Impact factor: 4.430

10.  Methotrexate-related lymphoproliferative disorder of the stomach in a patient with rheumatoid arthritis: a case of disease regression after methotrexate cessation.

Authors:  Kazuki Ikeda; Takefumi Nakamura; Takahiro Kinoshita; Mikio Fujiwara; Suguru Uose; Hitoshi Someda; Takashi Miyoshi; Katsuhiro Io; Ken-Ichi Nagai
Journal:  Clin J Gastroenterol       Date:  2016-01-05
View more
  1 in total

1.  Methotrexate-induced Primary Cutaneous Diffuse Large B-cell Lymphoma in Patients with Erythrodermic Cutaneous T-cell Lymphoma.

Authors:  Jérémie Delaleu; Eve Maubec; Francois Rodrigues; Annie Lévy; Vanessa Szablewski; Lilliane Laroche; Olivier Dereure
Journal:  Acta Derm Venereol       Date:  2020-08-17       Impact factor: 3.875
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.